GlassScriptPhysician profile
John F Freiler
NPI 1407863533
$5,588.16
in general payments reported to CMS, 2019-2025
24 companies · $1,508 in 2025
The $1,508 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $740 · 2020: $27.63 · 2021: $232 · 2022: $1,011 · 2023: $344 · 2024: $1,726 · 2025: $1,508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,555 · Education: $22.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,555.00 |
| Education | $22.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,458.19 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $517.87 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Genzyme Corporation | $474.53 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $468.58 | 2021-2025 | |
| Genentech USA, INC. | $465.64 | 2021-2025 | Xolair |
| Alk-Abello, INC | $388.04 | 2019-2025 | Ragwitek, Grastek, Odactra |
| Ars Pharmaceuticals Operations, INC. | $262.87 | 2025 | Neffy |
| Shire North American Group INC | $247.07 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $177.80 | 2024-2025 | Takhzyro, Cuvitru |
| Adma Biomanufacturing LLC | $160.13 | 2022 | |
| Jubilant Hollisterstier LLC | $143.43 | 2024 | |
| Genentech, INC. | $141.64 | 2024 | Xolair |
| Novartis Pharmaceuticals Corporation | $116.60 | 2025 | |
| Grifols USA, LLC | $110.29 | 2024 | Xembify |
| Octapharma USA, INC. | $107.59 | 2022-2025 | Cutaquig |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $85.66 | 2022 | |
| Kaleo, INC. | $46.48 | 2021-2023 | Auvi-Q |
| Greer Laboratories, INC. | $45.44 | 2021-2023 | Oralair |
| Amgen INC. | $43.44 | 2022-2025 | Tezspire |
| Csl Behring | $37.61 | 2022 | |
| Incyte Corporation | $28.98 | 2022 | |
| Phadia US INC. | $24.91 | 2024 | Immunocap |
| Bio Products Laboratory USA, INC. | $19.79 | 2022 | |
| Aimmune Therapeutics, INC. | $15.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Freiler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.